pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Sep 15·1 min read
save

Omada Health posts first profitable quarter and prepares CEO succession

Sep 15, 2026·read at Endpoints ↗EarningsPositive

Omada Health, a digital health company, completed its IPO a little over a year ago and has now posted its first profitable quarter, achieved in the spring.

The profitability marks a milestone for the firm, which has been focusing on scaling its chronic disease management platform.

With the financial results in hand, the board is preparing for its inaugural CEO transition, appointing Wei-Li Shao, who joined the company recently, to take over leadership.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Why Omada is staying in its lane”

read at Endpoints ↗
80 words · retrieved Sep 15
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoDraft COINS rules could threaten broad China collaborationsEndpoints
  • 2h agoLilly's ads can continue after Novo challenge, judge rulesEndpoints
  • 5h agoGubra looks beyond metabolism, hopes for first portfolio company this yearEndpoints
  • 5h agoArtiva to wind down after two patient deaths in autoimmune cell therapy trialsEndpoints
  • 5h agoOutpace ends an ovarian cancer trial; Incyte data impresses at ESMOEndpoints